Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 0

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
Item 1. Interim Financial Statements.

DRUGS MADE IN AMERICA ACQUISITION CORP.

BALANCE SHEETS

(UNAUDITED)

    June 30, 2025  
    December 31, 2024 

    ASSETS 

    Current assets 

    Cash 
    $822  
    $1,351 
  
    Prepaid expenses and other current assets 
     48,904  
     3,640 
  
    Total Current Assets 
     49,726  
     4,991 

    Deferred offering costs 
     —  
     545,833 
  
    Cash and investments held in Trust Account 
     235,155,966  
     — 
  
    TOTAL ASSETS 
    $235,205,692  
    $550,824 

    LIABILITIES AND SHAREHOLDERS’ DEFICIT 

    Current liabilities 

    Accounts payable and accrued expenses 
    $147,453  
    $77,280 
  
    Accrued offering costs 
     153,988  
     56,065 
  
    Promissory note – related party 
     —  
     662,324 
  
    Total Current Liabilities 
     301,441  
     795,669 

    Deferred underwriting fee payable 
     6,900,000  
     — 
  
    Total Liabilities 
     7,201,441  
     795,669 

    Commitments 

    Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.22 and $0 per share as of June 30, 2025 and December 31, 2024, respectively 
     235,155,966  
     — 

    Shareholders’ Deficit 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of June 30, 2025 and December 31, 2024 
     —  
     — 
  
    Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10,517,143 and 9,857,143 shares issued and outstanding, excluding 20,000,000 and 0 shares subject to redemption as of June 30